Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Rating) was the target of some unusual options trading activity on Wednesday. Investors bought 1,002 put options on the stock. This represents an increase of 1,791% compared to the average daily volume of 53 put options.
Institutional Investors Weigh In On Maravai LifeSciences
→ Know Your Profit Potential BEFORE You Trade! (From Tradewins)
A number of large investors have recently modified their holdings of MRVI. Bank of New York Mellon Corp grew its holdings in shares of Maravai LifeSciences by 1.5% during the first quarter. Bank of New York Mellon Corp now owns 416,617 shares of the company’s stock worth $14,694,000 after buying an additional 6,339 shares in the last quarter. Bank of Montreal Can increased its position in Maravai LifeSciences by 13.6% during the first quarter. Bank of Montreal Can now owns 16,563 shares of the company’s stock worth $591,000 after purchasing an additional 1,986 shares during the last quarter. MetLife Investment Management LLC purchased a new position in Maravai LifeSciences during the first quarter worth about $250,000. Dimensional Fund Advisors LP grew its stake in shares of Maravai LifeSciences by 534.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 117,159 shares of the company’s stock valued at $4,133,000 after buying an additional 98,698 shares during the period. Finally, Sei Investments Co. increased its holdings in shares of Maravai LifeSciences by 7.5% during the 1st quarter. Sei Investments Co. now owns 159,229 shares of the company’s stock worth $5,554,000 after buying an additional 11,079 shares during the last quarter. Hedge funds and other institutional investors own 48.67% of the company’s stock.
Maravai LifeSciences Price Performance
Maravai LifeSciences stock opened at $14.24 on Thursday. Maravai LifeSciences has a 52-week low of $12.16 and a 52-week high of $41.82. The firm has a market capitalization of $3.63 billion, a price-to-earnings ratio of 7.96 and a beta of -0.22. The company has a fifty day simple moving average of $14.03 and a 200-day simple moving average of $18.38. The company has a quick ratio of 6.68, a current ratio of 7.22 and a debt-to-equity ratio of 0.62.
Analyst Ratings Changes
Several analysts have commented on the stock. UBS Group cut shares of Maravai LifeSciences from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $20.00 to $16.00 in a research note on Thursday, January 5th. Credit Suisse Group decreased their target price on shares of Maravai LifeSciences from $34.00 to $26.00 and set an “outperform” rating for the company in a research note on Thursday, November 3rd. The Goldman Sachs Group decreased their target price on shares of Maravai LifeSciences from $18.00 to $16.00 and set a “buy” rating for the company in a research note on Tuesday, January 17th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Maravai LifeSciences in a research note on Tuesday, December 13th. They issued a “buy” rating and a $25.00 target price for the company. Finally, Morgan Stanley decreased their target price on shares of Maravai LifeSciences from $35.00 to $32.00 and set an “overweight” rating for the company in a research note on Friday, November 4th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Maravai LifeSciences has an average rating of “Moderate Buy” and a consensus target price of $23.00.
About Maravai LifeSciences
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Maravai LifeSciences, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Maravai LifeSciences wasn’t on the list.
While Maravai LifeSciences currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: marketbeat.com
